Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Slides:



Advertisements
Similar presentations
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Advertisements

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.
History of the randomized evidence on early breast cancer overall survival: Radiation vs no radiation after mastectomy L. Vakaet 2006.
ATLAS Steering Committee: 24 September 2005 Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools.
University of Toronto Province-Wide Oncology Rounds
Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,
Hot topics in breast radiotherapy Mark Beresford.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Study Of Letrozole Extension
Description of fracture with endocrine therapy use in older breast cancer survivors in a population-based setting Taryn Becker 123, Geoff Anderson 123,
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
These slides were released by the speaker for internal use by Novartis.
HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,
These slides were released by the speaker for internal use by Novartis.
Oral Bisphosphonate and Breast Cancer: Prospective Results from the Women’s Health Initiative (WHI) Chlebowski RT et al. SABCS 2009; Abstract 21.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Radiation Breast Oncology Highlights of SABC 2006 Alison Bevan, MD PhD UCSF Radiation Oncology January, 2007.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
These slides were released by the speaker for internal use by Novartis
Dubsky P et al. Proc SABCS 2012;Abstract S4-3.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
A systematic meta-analysis of randomized controlled trials for adjuvant chemotherapy for localized resectable soft-tissue sarcoma Nabeel Pervaiz Nigel.
San Antonio Breast Cancer Symposium 2012 Helen K. Chew, MD, FACP Professor of Medicine.
The ‘Arimidex’, Tamoxifen Alone or in Combination (ATAC) trial: Completed Treatment Analysis Questions & Answers / Issues Management.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year.
Start or Switch?: Latest data from ABCSG/ARNO
Published online July 24, Aromatase inhibitors versus tamoxifen in early breast.
Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831.
Trial Comparison: ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) and Breast International Group (BIG) 1-98.
Adjuvant chemotherapy – When should surgeons recommend? Joint Hospital Surgical Grand Round Dr Lorraine Chow Ruttonjee Hospital.
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
“Big Data, Better Treatment”: The work of the Early Breast Cancer Trialists’ Collaborative Group Rory Collins BHF Professor of Medicine & Epidemiology.
Anastrozole (‘Arimidex’): a new standard of care?
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal.
Lectures inEarly Breast Cancer A PowerPoint slide set based on images from: Lectures in Early Breast Cancer Part 3: Adjuvant Therapy in Early Breast Cancer.
Inferring the Effects of Cancer Treatment: Divergent Results from the Early Breast Cancer Trialists’ Collaborative Group Meta-analyses of Randomized Trials.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer Bryan P. Schneider,
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.
The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.
J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in post-menopausal.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials Lancet 2010;
CCO Independent Conference Coverage
San Antonio Breast Cancer Symposium. December
Paper of The Week Follow-up may not be beneficial after treatment of grade 1 breast cancer M. Kontos, D. Allen, D. T. Trafalis, G. Jones, H. Garmo, L.
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
THE EFFECTIVENESS OF ANNUAL ZOLEDRONIC ACID INFUSION VERSUS ORAL BISPHOSPHONATE: A MODELLING APPROACH Terence Ong1, 2, Matthey Jones3, Opinder Sahota1.
Early Breast Cancer Clinical Trialists’ Collaborative Group
Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting
Effect of Obesity on Prognosis after Early Breast Cancer
Volume 386, Issue 10001, Pages (October 2015)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised.
Volume 386, Issue 10001, Pages (October 2015)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials 
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient.
20-Year Risks of Breast-Cancer Recurrence
Published online Feb 7, 2019 Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling:
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Presentation transcript:

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) www.thelancet.com Published online July 24, 2015 http://dx.doi.org/10.1016/S0140-6736(15)60908-4

Bisphosphonates: statistical analysis plan Primary outcomes Time to recurrence: includes distant recurrence, local recurrence and new second primary breast cancer (ipsilateral or contralateral), and the definitions of these will be as in each trial. Time to first distant recurrence: includes distant recurrence and ignores any prior loco-regional or contralateral recurrences. Breast cancer mortality: by logrank subtraction.

Primary subgroup analyses Site of recurrence (distant metastasis, local recurrence or contralateral breast cancer) Site of distant metastasis (bone±other, not bone) Menopausal status: Premenopausal (or <45 if U/K); perimenopausal (or 45-54 if U/K), postmenopausal (natural/induced) or 55+ if U/K; Type of bisphosphonate (aminobisphosphonate, other, ie clodronate)

Other planned subgroup analyses Bisphosphonate agent Age (<45, 45-54, 55-69, ≥70, unknown); ER status (ER-poor, ER+, unknown); Nodal status (negative, positive, N1-3, N4+, N unknown); Histological grade (1, 2, 3, unknown); Presence/ absence of chemotherapy; and Follow-up period (years 0-1, 2-4, 5-9, and 10+ after randomisation).

Data received: 18,766 women Total: All regimens Trials Patients %   Studies identified   Studies with data received   Trials Patients % Years <1 year clodronate 2 120 1 72 60 0·5 <1 year aminobisphosphonate 208 40 19 0·1 1 year aminobisphosphonate 7 1088 3 448 41 1·0 Subtotal: ≤1 year of treatment 11 1416 5 560 40% 0·9 2 years clodronate 4 3978 3912 98 2·0 3-5 years clodronate 1069 100 3.0 2 years aminobisphosphonate 10 3654 8 3514 96 3-5 years aminobisphosphonate 12 11 910 9 9711 82 4·5 Subtotal: 2-5 yrs of treatment 27 20 611 21 18 206 88% 3·5 Any clodronate regimen 5167 5053 2·6 Any aminobisphosphonate‡ 31 16 860 13 713 81 3·8  Total: All regimens 38 22 027 26 18 766 85% 3·4

Bisphosphonates: Recurrence Any recurrence Distant recurrence

Bisphosphonates: mortality Breast cancer mortality All-cause mortality

Primary subgroup analyses Site of recurrence (distant metastasis, local recurrence or contralateral breast cancer)

Subgroup analyses by site of recurrence

BSP: Local and contralateral recurrence Local recurrence Contralateral breast recurrence

Primary subgroup analyses Site of recurrence (distant metastasis, local recurrence or contralateral breast cancer) Site of distant metastasis (bone±other, not bone)

BSP: site of distant recurrence Bone recurrence Other distant recurrence

Subgroup analyses by site of recurrence

Primary subgroup analyses Site of recurrence (distant metastasis, local recurrence or contralateral breast cancer) Site of distant metastasis (bone±other, not bone) Menopausal status: Premenopausal (or <45 if U/K); perimenopausal (or 45-54 if U/K), postmenopausal (natural/induced) or 55+ if U/K;

>5 years post-menopausal AZURE (hypothesis generating trial): Effects of zoledronic acid on Invasive DFS by Menopausal Status Pre, peri and unknown menopausal status >5 years post-menopausal Adjusted HR 1.03 95% CI: 0.89-1.20 Adjusted HR 0.77 95% CI: 0.63-0.96 Control Zoledronic acid N = 2318 702 events Control Zoledronic acid N = 1041 347 events No. at risk Control ZOL No. at risk Control ZOL Menopausal Interaction: 21 =4.71; P=0.030

EBCTCG meta-analysis of bone recurrence by menopause: all trials

Bone recurrence by age: all trials

Bone recurrence by menopause and age Without AZURE and ABCSG XII

Bone recurrence by menopausal status Premenopausal Postmenopausal

Non-bone distant recurrence by menopause Premenopausal Postmenopausal

Any distant recurrence by menopause Premenopausal Postmenopausal

Breast cancer mortality by menopausal status Premenopausal Postmenopausal

Primary subgroup analyses Site of recurrence (distant metastasis, local recurrence or contralateral breast cancer) Site of distant metastasis (bone±other, not bone) Menopausal status: Premenopausal (or <45 if U/K); perimenopausal (or 45-54 if U/K), postmenopausal (natural/induced) or 55+ if U/K; Type of bisphosphonate: aminobisphosphonate, other (clodronate)

Bone recurrence by bisphosphonate type

Other subgroup analyses Based on bone recurrence in all bisphosphonate trials

Bone recurrence by BSP dose, duration, absence/presence of chemotherapy

Bone recurrence by year of follow-up

Bone recurrence by ER, nodal status and grade

Non-breast cancer events Non-breast cancer death Bone fracture

Bisphosphonates – conclusions* Fewer bone recurrences with bisphosphonate Benefits appear to be confined to postmenopausal/ older women Among postmenopausal women, significant reductions in any recurrence, distant recurrence, and breast cancer mortality Fewer bone fractures and no effect on non-breast cancer mortality *EBCTCG, Lancet, published online July 24, 2015: http://dx.doi.org/10.1016/S0140-6736(15)60908-4

Acknowledgements We thank the tens of thousands of women who took part in the trials, the many staff in trial centres and participating clinics who helped conduct the trials, and the trialists who shared their data. This presentation was prepared by Rosie Bradley and Richard Gray of the EBCTCG Secretariat, which is funded through direct support from Cancer Research UK and the UK Medical Research Council, to the Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK.